No Data
No Data
Goldman Sachs To Rally Around 8%? Here Are 10 Top Analyst Forecasts For Tuesday
Express News | Wedbush Reiterates Outperform on Artiva Biotherapeutics, Maintains $18 Price Target
Artiva Biotherapeutics Is Maintained at Overweight by Cantor Fitzgerald
Artiva Biotherapeutics Price Target Cut to $20.00/Share From $23.00 by Cantor Fitzgerald
Express News | Needham Reiterates Buy on Artiva Biotherapeutics, Maintains $23 Price Target
Artiva Biotherapeutics Analyst Ratings